Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH management in PLWH

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Feb 16, 2022 5:44pm

83 Views

Post# 34435621

RE:RE:NASH management in PLWH

I have not had time to listen - did he say anything worthwhile?

realitycheck4u wrote: He almost sounded like a computer, or like a guy reading a prepared paper who was 'paid for hire'. Then I saw "Educational grant provided by Theratechnologies Inc. at the bottom"

scarlet1967 wrote: If you jump to 5th minute the speaker makes a reference to Tesamorelin...
https://www.clinicaloptions.com/diabetes/programs/2021/hiv-and-nash/podcast/podcast-3